Use of dydrogesterone as a progestogen for oral contraception

Steroids

Volumn 68, Issue 10-13, 2003, Pages 927-929

  Coelingh Bennink, Herjan J T ^a   Boerrigter, Peter J ^a  

^a Pantarhei Bioscience   (Netherlands)

Author keywords

Contraception; Dydrogesterone; Retrosteroid

Indexed keywords

ANABOLIC AGENT; ANDROGEN; DYDROGESTERONE; GESTAGEN; GLUCOCORTICOID; STEROID;

ADULT; CLINICAL PRACTICE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN ACTIVITY; FEMALE; HEADACHE; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; MOOD DISORDER; NORMAL HUMAN; ORAL CONTRACEPTION; SIDE EFFECT;

EID: 0346366919     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2003.07.006     Document Type: Conference Paper

References (26)

1. van Amsterdam P.H., Overmars H., Scherpenisse P.M., de Bree H. Dydrogesterone: Metabolism in man. Eur. J. Drug Metab. Pharmacokinet. 5:1980;173-184.
2. Backer M.H. Isopregnenone (Duphaston): a new progestational agent. Obstet. Gynecol. 19:1962;724-729.
3. Barentsen R., van de Weijer P.H.M. Progestogens: pharmacological characteristics and clinically relevant differences. Eur. Menopause J. 3:1996;266-271.
4. Overton C.E., Lindsay P.C., Johal B., Collins S.A., Siddle N.C., Shaw R.W., Barlow D.H. A randomized, double-blind, placebo-controlled study of luteal phase dydrogesterone (Duphaston)in women with minimal to mild endometriosis. Fertil. Steril. 62:1994;701-707.
5. Balasch J., Vanrell J.A., Marquez M., Burzaco I., Gonzalez-Merlo J. Dydrogesterone versus vaginal progesterone in the treatment of the endometrial luteal phase deficiency. Fertil. Steril. 37:1982;751-754.
6. Kupfermine M.J., Lessing J.B., Amit A., Yovel I., David M.P., Peyser M.R. A prospective randomized trial of human chorionic gonadotrophin or dydrogesterone support following in-vitro fertilization and embryo transfer. Hum. Reprod. 5:1990;271-273.
7. Belaisch-Allart J., Testart J., Fries N., Forman R.G., Frydman R. The effect of dydrogesterone supplementation in an IVF programme. Hum. Reprod. 2:1987;183-185.
8. Radulesco J.C. La Dydrogesterone dans le traitement des grossesses hypohormonales. Marseille Medical. 107:1970;191-196.
9. El-Zibdeh M.Y. Randomized study comparing the efficacy of reducing spontaneous abortion following treatment with a progesterone (Dydrogesterone) and human chorionic gonadotrophin (hCG). Fertil. Steril. 70(1S):1998;77-78.
10. Haspels AA. A double-blind, placebo-controlled, multi-center study of the efficacy of dydrogesterone (Duphaston). In: van Keep PA, Utian WH, editors. The premenstrual syndrome. Lancaster, England: MTP Press Limited; 1981. pp. 81-92.
11. Sampson G.A., Heathcote P.R.M., Wordsworth J., Prescott P., Hodgson A. Premenstrual syndrome. A double-blind cross-over study of treatment with dydrogesterone and placebo. Br. J. Psychiatr. 153:1988;232-235.
12. Hoffmann V., Pedersen P.A., Philip J., Fly P., Pedersen C. The effect of dydrogesterone on premenstrual symptoms. A double-blind, randomized, placebo-controlled study in general practice. Scand. J. Prim. Health Care. 6:1988;179-183.
13. Ohlenroth G., Hatzmann W. Die Therapie der juvenilen Dysmenorrhö mit 6-Dehydro-Retro-Progesteron. Med. Welt. 33:1982;645-646.
14. Nakamura S., Douchi T., Oki T., Ijuin H., Yamamoto S., Nagata Y.et al. Relationship between sonographic endometrial thickness and progestin-induced withdrawal bleeding. Obstet. Gynecol. 87/5(Part 1):1996;722-725.
15. Battino S., Ben-Ami M., Geslevich Y., Weiner E., Shalev E. Factors associated with withdrawal bleeding after administration of oral dydrogesterone or medroxyprogesterone acetate in women with secondary amenorrhoea. Gynecol. Obstet. Invest. 42:1996;113-116.
16. Sipowicz I., Chomczyk I. Efficacy of dydrogesterone in the treatment of cycle disturbances in adolescence. Gin. Pol. 69(9):1998;768-770.
17. Chomczyk I., Sipowicz M., Sipowicz I. Dydrogesterone in the regulation of cycle disturbances in adolescence. Gin. Pol. 70:1999;343-347.
18. Foster R.H., Balfour J.A. Estradiol and dydrogesterone. A review of their combined use as hormone replacement therapy in postmenopausal women. Drugs Aging. 11(4):1997;309-332.
19. Crook D., Godsland I.F., Stevenson J.C. The cardiovascular risk profile of hormone replacement therapies containing dydrogesterone: a review. Eur. Menopause J. 2:1995;23-30.
20. Stevenson J.C., Teter P., Lees B. 17β-estradiol (1 mg/day)continuously combined with dydrogesterone (5, 10 or 20 mg/day)increases bone mineral density in postmenopausal women. Maturitas. 38:2001;197-203.
21. Bernard I. Comparason clinique des nouveaux progestagènes. Gynecol. Prat. 13:1962;477-496.
22. Ullery J.C., DeNeef J.C., Holzaepfel J.H. Dydrogesterone therapy: clinical observations and laboratory findings in 61 patients. Obstet. Gynecol. 22:1963;38-45.
23. Netter A., Yaneva H., Salomon-Bernard Y. Notre expérience with dydrogésterone. C.R. Soc. Fr. Gynecol. 5:1962;395-401.
24. Brotherton J. Animal biological assessment. In: Sex hormone pharmacology. London: Academic Press; 1976. pp. 42-78.
25. ®)on ovulation in the rat, rabbit and monkey. Acta. Endocrin. 67:1971;551-562.
26. Van Heusden A.M., Fauser B.C. Residual ovarian activity during oral combined steroid contraception. Hum. Reprod. Update. 8:2002;345-358.